Entrada Therapeutics Inc
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV")-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a varie… Read more
Entrada Therapeutics Inc (TRDA) - Total Liabilities
Latest total liabilities as of September 2025: $72.18 Million USD
Based on the latest financial reports, Entrada Therapeutics Inc (TRDA) has total liabilities worth $72.18 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Entrada Therapeutics Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Entrada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Entrada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Entrada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Probe Metals Inc
OTCQB:PROBF
|
USA | $12.58 Million |
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
China | CN¥1.14 Billion |
|
Cabaletta Bio Inc
NASDAQ:CABA
|
USA | $50.29 Million |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
China | CN¥1.83 Billion |
|
Shanghai Flyco Electrical Appliance Co Ltd
SHG:603868
|
China | CN¥624.18 Million |
|
Hextar Global Bhd
KLSE:5151
|
Malaysia | RM552.20 Million |
|
MediaAlpha Inc.
NYSE:MAX
|
USA | $332.01 Million |
|
GSW Immobilien AG
HM:GIB
|
Germany | €4.17 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Entrada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entrada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entrada Therapeutics Inc (2019–2024)
The table below shows the annual total liabilities of Entrada Therapeutics Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $97.64 Million | -56.95% |
| 2023-12-31 | $226.83 Million | +474.23% |
| 2022-12-31 | $39.50 Million | +455.19% |
| 2021-12-31 | $7.12 Million | -91.63% |
| 2020-12-31 | $85.02 Million | +151.86% |
| 2019-12-31 | $33.76 Million | -- |